Mesoblast (MEOBF) Cash from Operations Growth (1y) (2015 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) Cash from Operations Growth (1y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 41.84% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 9.83% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -58.33% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -24.59% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 97.11% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 893.58% |
| Mar 31, 2023 | -402.47% |
| Dec 31, 2022 | 190.31% |
| Sep 30, 2022 | -21.50% |
| Jun 30, 2022 | 26.56% |
| Mar 31, 2022 | 36.78% |
| Dec 31, 2021 | 40.42% |
| Sep 30, 2021 | 164.61% |
| Mar 31, 2021 | 33.47% |
| Dec 31, 2020 | -81.08% |
| Sep 30, 2020 | -81.05% |
| Mar 31, 2020 | -73.59% |
| Dec 31, 2019 | -762.95% |
| Sep 30, 2019 | 20.40% |
| Mar 31, 2019 | -8.09% |
| Dec 31, 2018 | 86.83% |
| Sep 30, 2018 | 3.99% |
| Jun 30, 2018 | 13.86% |
| Mar 31, 2018 | 23.64% |
| Dec 31, 2017 | 41.79% |